Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 303Carcinoma, Non-Small-Cell Lung 240Prostatic Neoplasms 196Neoplasms 190Lung Neoplasms 149Multiple Myeloma 141Neoplasm Metastasis 110Colorectal Neoplasms 104Melanoma 97Ovarian Neoplasms 90Leukemia, Myeloid, Acute 82Pancreatic Neoplasms 76Lymphoma 76Leukemia, Lymphocytic, Chronic, B-Cell 71Brain Neoplasms 69Carcinoma, Renal Cell 67Squamous Cell Carcinoma of Head and Neck 62Lymphoma, Non-Hodgkin 62Carcinoma, Hepatocellular 61Hematologic Neoplasms 60Urinary Bladder Neoplasms 58Head and Neck Neoplasms 56Triple Negative Breast Neoplasms 55Recurrence 54Glioblastoma 53Uterine Cervical Neoplasms 51Lymphoma, Follicular 51Endometrial Neoplasms 50Stomach Neoplasms 46Sarcoma 46

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Breast Carcinoma × 90 days × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡